Dr. Ignacio Garrido-Laguna, MD

Dr. Garrido-Laguna practices at University of Utah Hospitals and Clinics - Unit in Salt Lake City, Utah.

Dr. Garrido-Laguna's NPI, 1467608554, was assigned on August 8, 2008. Dr. Garrido-Laguna holds Utah license 8041621-1252.

Dr. Garrido-Laguna's primary practice is University of Utah Hospitals and Clinics - Unit, at 50 North Medical Drive, Salt Lake City, UT 84132 in Salt Lake County. The practice phone is (801) 581-2337.

Dr. Garrido-Laguna's primary practice is University of Utah Hospitals and Clinics - Unit in Salt Lake City, Utah. Dr. Garrido-Laguna is also affiliated with University of Utah Hospital. The medical group on file is University of Utah Health. Dmand AI also links Dr. Garrido-Laguna to 1 more group practice or clinic, named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Garrido-Laguna practices, 3 sites in all. Vendor and product names are available with a free account.

Medical oncology is Dr. Garrido-Laguna's primary specialty in the NPI Registry, under taxonomy code 207RX0202X. Dr. Garrido-Laguna is licensed in Utah.

CMS data shows 415 Medicare services from Dr. Garrido-Laguna across 4 procedure codes in 2024, for 109 Medicare patients. Medicare paid $30,206 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 109 Medicare patients who saw Dr. Garrido-Laguna in 2024. The largest group is 65 to 74, with 64 patients. 66% of them have high blood pressure, and 53% have high cholesterol. Their average risk score is 2.72, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Garrido-Laguna's median patient age at 71, with 45% women.

In 2024, Dr. Garrido-Laguna wrote 49 Medicare Part D claims for 22 patients. 96% of them were for generic drugs. CMS names the drug for 26 of them, across 2 drugs with 11 or more claims each, at $65,927 in total drug cost. In 2022, CMS named 15 claims across 1 drug.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 90 out of 100 for Dr. Garrido-Laguna for performance year 2024, reported as part of a group. Dr. Garrido-Laguna accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Garrido-Laguna as offering telehealth.

Dmand AI links 76 papers to Dr. Garrido-Laguna, published from 2011 to 2025. 2021 was the busiest year, with 7. The most frequent topics are Pancreatic Neoplasms, Antineoplastic Combined Chemotherapy Protocols and Carcinoma, Pancreatic Ductal. Dr. Garrido-Laguna has published most often in J Natl Compr Canc Netw. Dr. Garrido-Laguna's most frequent co-authors are Christopher Duane Nevala-Plagemann, Vaia Florou, MD and Shane Lloyd, MD.

Dmand AI links Dr. Garrido-Laguna to 11 clinical trials, 4 of them phase 2 studies. 5 are still active or recruiting. Conditions studied include Pancreatic Neoplasms, Pancreatic Diseases and Anus Neoplasms. National Cancer Institute (NCI) sponsors the most, 4. Open Payments lists research payments to Dr. Garrido-Laguna that name 1 trial.

CMS Open Payments shows 48 general payments to Dr. Garrido-Laguna from 12 drug and device companies from 2016 to 2025. Consulting fees make up the largest share, 50% of the total. Pfizer Inc. paid the most, $9,978. It also lists 33 research payments totaling $55,818 from 2018 to 2022, naming 1 clinical trial.